2013 - EpiVax, Inc. - Informatics and Immunology

T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation

by Sarah Moniz | Aug 15, 2018

Development of Scoring Functions for Antibody Sequence Assessment and Optimization

by epivax3 | Oct 22, 2016

Development of Scoring Functions for Antibody Sequence Assessment and Optimization. Boehringer Ingelheim Pharma PLoS One. 2013; 8(10) [Use of ISPRI tool to develop Humanized antibody concept].

Building Better Biotherapeutics and Vaccines by Design: EpiVax, Inc., an Immunology Company

by epivax3 | Oct 22, 2016

Rhode Island Medical Journal, February 2013. rimed.org/rimedicaljournal/2013-02/2013-02-19-bio-epivax.pdf

Computational vaccinology and the ICoVax 2012 workshop

by epivax3 | Oct 22, 2016

BMC Bioinformatics. 2013;14 Suppl 4:I1.doi: 10.1186/1471-2105-14-S4-I1. Epub 2013 Mar 8. PubMed PMID: 23514034; PubMed Central PMCID: PMC3599086.

Universal H1N1 influenza vaccine development: Identification of consensus class II hemagglutinin and neuraminidase epitopes derived from strains circulating between 1980 and 2011

by epivax3 | Oct 22, 2016

Human Vaccines & Immunotherapeutics 2013; 9:1598 – 1607; PMID: 23846304; https://dx.doi.org/10.4161/hv.25598

T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation

Development of Scoring Functions for Antibody Sequence Assessment and Optimization

Building Better Biotherapeutics and Vaccines by Design: EpiVax, Inc., an Immunology Company

Computational vaccinology and the ICoVax 2012 workshop

Universal H1N1 influenza vaccine development: Identification of consensus class II hemagglutinin and neuraminidase epitopes derived from strains circulating between 1980 and 2011

Recent Posts

Categories